Lipella Pharmaceuticals Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for Lipella Pharmaceuticals.

Analyst Consensus: n/a

Target	Low	Average	Median	High
Price	n/a	n/a	n/a	n/a
Change	n/a	n/a	n/a	n/a

Analyst Ratings

There are currently no analyst ratings available for Lipella Pharmaceuticals.

Recommendation Trends

Rating	Apr '24
Strong Buy	0
Buy	0
Hold	0
Sell	0
Strong Sell	0
Total	0

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jason McCarthy Maxim Group	Maxim Group	Strong Buy Initiates $16	Strong Buy	Initiates	$16	+553.06%	Apr 9, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

from 536.36K

Revenue Next Year

n/a

EPS This Year

-5.30

from -4.79

EPS Next Year

-17.77

from -5.30

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	961.68K	259.35K	184.16K	449.62K	536.36K	-	-	-
Revenue Growth	38.42%	-73.03%	-28.99%	144.15%	19.29%	-	-	-
EPS	-0.23	-4.40	-5.12	-6.16	-4.79	-5.30	-17.77	-2.22
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	3	3	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026
High	n/a	n/a
Avg	n/a	n/a
Low	n/a	n/a

Revenue Growth

Revenue Growth	2025	2026
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2025	2026	2027
High	-5.46	-18.29	-2.29
Avg	-5.30	-17.77	-2.22
Low	-5.10	-17.07	-2.14

EPS Growth

EPS Growth	2025	2026	2027
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.